bupropion has been researched along with Genetic Predisposition in 10 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To identify replicated genes that facilitate smokers' abilities to achieve and sustain abstinence from smoking (herein after referred to as quit-success genes) found in more than 2 genome-wide association (GWA) studies of successful vs unsuccessful abstainers, and, secondarily, to nominate genes for selective involvement in smoking cessation success with bupropion hydrochloride vs nicotine replacement therapy (NRT)." | 5.13 | Molecular genetics of successful smoking cessation: convergent genome-wide association study results. ( David, SP; Drgon, T; Johnson, C; Lerman, C; Liu, QR; Niaura, R; Rose, JE; Uhl, GR; Walther, D, 2008) |
| "This study evaluated the ability of polymorphisms in five candidate genes to predict weight gain among patients taking bupropion or placebo in a smoking cessation trial." | 5.12 | No evidence for a major role of polymorphisms during bupropion treatment. ( Allison, DB; Berrettini, WH; Hu, J; Lerman, C; Pinto, A; Redden, DT; Restine, SL; Shields, PG, 2006) |
| "Novel pharmacotherapies for nicotine dependence include partial agonists for nicotinic receptors and nicotine vaccines." | 2.44 | Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. ( Benowitz, NL, 2008) |
| "Smoking cessation is associated with a 65% reduction in the risk of a relapse as compared with continued smokers, a similar magnitude to that obtained with immunosuppressive therapy." | 2.43 | Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. ( Cosnes, J; Johnson, GJ; Mansfield, JC, 2005) |
| " Pharmacokinetic analysis was performed by non-parametric methods and by population pharmacokinetic modelling." | 1.32 | Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ( Brockmöller, J; Kirchheiner, J; Klein, C; Meineke, I; Mürdter, TE; Roots, I; Sasse, J; Zanger, UM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uhl, GR | 1 |
| Liu, QR | 1 |
| Drgon, T | 1 |
| Johnson, C | 1 |
| Walther, D | 1 |
| Rose, JE | 1 |
| David, SP | 1 |
| Niaura, R | 1 |
| Lerman, C | 3 |
| Bergen, AW | 1 |
| Conti, DV | 1 |
| Van Den Berg, D | 1 |
| Lee, W | 1 |
| Liu, J | 1 |
| Li, D | 1 |
| Guo, N | 1 |
| Mi, H | 1 |
| Thomas, PD | 1 |
| Lessov-Schlaggar, CN | 1 |
| Krasnow, R | 1 |
| He, Y | 1 |
| Nishita, D | 1 |
| Jiang, R | 1 |
| McClure, JB | 1 |
| Tildesley, E | 1 |
| Hops, H | 1 |
| Tyndale, RF | 2 |
| Benowitz, NL | 2 |
| Swan, GE | 1 |
| Clark, SL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Hettema, JM | 1 |
| McClay, JL | 1 |
| Souza, RP | 1 |
| van den Oord, EJ | 1 |
| Kirchheiner, J | 1 |
| Klein, C | 1 |
| Meineke, I | 1 |
| Sasse, J | 1 |
| Zanger, UM | 1 |
| Mürdter, TE | 1 |
| Roots, I | 1 |
| Brockmöller, J | 1 |
| Johnson, GJ | 1 |
| Cosnes, J | 1 |
| Mansfield, JC | 1 |
| Berrettini, WH | 2 |
| Lerman, CE | 1 |
| Al Koudsi, N | 1 |
| Hu, J | 1 |
| Redden, DT | 1 |
| Shields, PG | 1 |
| Restine, SL | 1 |
| Pinto, A | 1 |
| Allison, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease[NCT01540942] | 91 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Developing Genetic Education for Smoking Cessation[NCT01186016] | 103 participants (Actual) | Interventional | 2010-02-01 | Completed | |||
| The Appeal and Impact of E-cigarettes in Smokers With Serious Mental Illness[NCT03050853] | 240 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations[NCT01156610] | 706 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Smokers' Response to Nicotine Dependence Genotyping[NCT01780038] | 24 participants (Actual) | Interventional | 2012-11-14 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Knowledge of genetic contributions to smoking. Name of Scale: Genetic Knowledge Test (9 items). Minimum/Maximum Scores: 0-9. Higher score means better outcome. (NCT01186016)
Timeframe: One week after completion of the two Educational Sessions (GES or NES). Educational sessions occurred over two weeks.
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | End of Educational Sessions | |
| Genetic Education Session (GES) | 5.25 | 7.04 |
| Nutrition Education Session (NES) | 3.73 | 4.03 |
Self-efficacy for Quitting/Resisting Smoking. Self-efficacy/Temptation Scale (Velicer, DiClemente, Rossi & Prochaska, 1990) Total Score. Scores range from 1 to 5, with higher scores indicating greater self-efficacy. Source: Velicer, W.F., DiClemente, C.C., Rossi, J.S., & Prochaska, J.O. (1990). Relapse situations and self-efficacy: An integrative model. Addictive Behaviors, 15, 271-283. (NCT01186016)
Timeframe: Six weeks after the baseline data collection, which was the end of the Smoking Cession Sessions.
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | End of Educational Sessions | End of Smoking Cessation Sessions | |
| Genetic Education Session (GES) | 3.93 | 3.80 | 2.73 |
| Nutrition Education Session (NES) | 3.99 | 3.86 | 2.57 |
4 reviews available for bupropion and Genetic Predisposition
| Article | Year |
|---|---|
Review article: smoking cessation as primary therapy to modify the course of Crohn's disease.
Topics: Behavior Therapy; Bupropion; Cohort Studies; Colitis, Ulcerative; Counseling; Crohn Disease; Dopamin | 2005 |
Pharmacotherapy and pharmacogenetics of nicotine dependence.
Topics: Administration, Cutaneous; Administration, Intranasal; Animals; Animals, Genetically Modified; Bupro | 2005 |
Genetic influences on smoking: a brief review.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Genetic Linkage; Genetic Predisposition to Dise | 2005 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American | 2008 |
4 trials available for bupropion and Genetic Predisposition
| Article | Year |
|---|---|
Molecular genetics of successful smoking cessation: convergent genome-wide association study results.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Chromosome Mapping; Controlled | 2008 |
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Topics: Adult; Analysis of Variance; Bupropion; Cohort Studies; DNA-Binding Proteins; Dopamine Plasma Membra | 2009 |
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Topics: Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Drug-Related Side Effects | 2012 |
No evidence for a major role of polymorphisms during bupropion treatment.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Genetic Predisposition to | 2006 |
2 other studies available for bupropion and Genetic Predisposition
| Article | Year |
|---|---|
Smoking and depression.
Topics: Bupropion; Depression; Genetic Predisposition to Disease; Humans; Smoking; Tobacco Use Disorder; Uni | 2002 |
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Chromatography, High Pressure Liq | 2003 |